Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business acquisition

GSK Acquires Chimagen Multiple Myeloma TCE

Analysis based on 8 articles · First reported Sep 15, 2026 · Last updated Sep 15, 2026

Sentiment
10
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The deal is a modest bolt-on acquisition for GSK that strengthens its oncology pipeline and multiple myeloma portfolio without materially altering near-term earnings, and GSK shares rose around 0.92 percent in overnight NYSE activity. Sentiment for the broader biotech sector is mildly positive as it signals continued large-pharma appetite for clinical-stage multi-specific antibody assets, though the transaction is too small to move the wider market.

pharmaceuticals biotechnology oncology

GSK plc announced on September 15, 2026 that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma from privately held clinical-stage biotechnology firm Chimagen Biosciences. The agreement has a total potential value of up to $750 million, comprising an upfront payment for full global rights to the TCE programme plus success-based development and commercial milestone payments, and remains subject to customary closing conditions. The candidate is designed to bind to T cells while simultaneously targeting two strategically selected and validated tumour-associated antigens, aiming to improve on the efficacy and tolerability limitations of existing TCE therapies. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter phase I trials in 2027. The deal complements GSK's existing multiple myeloma franchise, which includes Blenrep (belantamab mafodotin), and builds on a prior agreement with Chimagen to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted TCE currently in phase I trials for B-cell malignancies and B-cell dependent autoimmune disorders. GSK cited forecasts that the US TCE market for multiple myeloma could exceed $10 billion by 2032. Multiple myeloma is the third most common blood cancer globally, with approximately 180,000 new cases diagnosed each year, and remains generally incurable. Noor Hisham Abdullah, Senior Vice President and Global Head of Oncology R&D at GSK, said the deal secures a promising T cell engager and advances GSK's leadership goals in blood cancer. Zhenhao Zou, CEO of Chimagen Biosciences, said the agreement marks another major milestone for the company's platforms.

95 GSK plc acquired global rights Chimagen Biosciences
40 GSK plc agreed to acquire Chimagen Biosciences
stock
GSK is the acquirer, paying up to $750 million for full global rights to Chimagen's trispecific TCE, expanding its multiple myeloma franchise alongside Blenrep and its broader oncology pipeline. The deal is strategically positive but financially small relative to GSK's scale, and its shares gained around 0.92 percent in overnight trading.
Importance 100.0 Sentiment 15.0
priv
Chimagen Biosciences is the privately held seller of the trispecific TCE, receiving an upfront payment plus up to $750 million in milestone payments and gaining GSK's global development and commercial capabilities for its programme. The agreement also deepens its existing relationship with GSK following the earlier CMG1A46 deal.
Importance 90.0 Sentiment 40.0
per
Noor Hisham Abdullah, GSK's Senior Vice President and Global Head of Oncology R&D, publicly commented that the deal secures a promising T cell engager and advances GSK's leadership goals in blood cancer.
Importance 20.0 Sentiment 5.0
per
Zhenhao Zou, CEO of Chimagen Biosciences, stated that working with GSK combines Chimagen's precision T-cell engager programme with GSK's global development and commercial capabilities and marks another major milestone for its platforms.
Importance 15.0 Sentiment 5.0
priv
Precigenetics is mentioned only as a better-ranked biotech stock in the sector comparison, with no direct role in the GSK-Chimagen transaction.
Importance 5.0 Sentiment 0.0
priv
Immunefi is mentioned only as a better-ranked biotech stock in the sector comparison, with no direct role in the GSK-Chimagen transaction.
Importance 5.0 Sentiment 0.0
stock
Aldeyra Therapeutics is mentioned only as a better-ranked biotech stock in the sector comparison, with no direct role in the GSK-Chimagen transaction.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.